Belmar compounds their semaglutide as a combination product: cyanocobalamin/semaglutide injection
GLP-1 agonists are being used in combination with basal insulin (Dungan & DeSantis, 2016), although this is not an FDA-approved indication (see rxlist.com) they should not be used as a substitute for basal insulin, as this has been found to result in a decline in glycemic control)(Dungan & DeSantis, 2016) Clinical trials indicate it can reduce HbA1c by ~0.8% Undergoes renal clearance, with dosage reduction needed if creatinine clearance falls to 1.5
Cell envelope fragments of Gram-negative bacteria can trigger anti-bacterial responses and inflammation, yet recent studies indicate that cell envelope fragments from A
In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder:a systematic review and meta-analysis
Contraindications and cautions : Be aware of specific situations where one or both medications should be avoided or used with extreme caution: Pregnancy : Both medications should be avoided in pregnancy
